ELMWOOD
PARK, N.J., Nov. 28,
2023 /PRNewswire/ --
BioReference® Health, LLC (BRH), a leading
specialty laboratory in the United
States, announced a strategic collaboration with Prognos
Health, a pioneer in providing accessible, quality real world data
("RWD") for the pharmaceutical and life science industries. This
collaborative arrangement will offer healthcare providers and
researchers unique solutions to inform clinical studies and improve
patient outcomes. Combining genetic data and critical biomarkers,
means targeted precision therapies based on patients' genetic
profiles will be more readily available.
BioReference and Prognos collaborate to
offer healthcare providers and researchers unique RWD
solutions.
The collaboration combines BioReference Health's expertise in
genomic data analysis with Prognos Health's managed RWD
marketplace. Prognos is accelerating the development and delivery
of innovative therapies and provides an unparalleled collection of
health records on more than 325 million de-identified patient
health records. Adding genomics will create even more solutions for
patients and healthcare providers.
"Precision medicine holds immense potential to transform
healthcare outcomes, and this agreement comes at a time when the
global healthcare industry is recognizing the immense value of RWD
in advancing precision medicine," said Anuj
Kalsy, Lead, Data & Strategy, and Sr. Director of
Pharmaceutical Arrangements at BioReference Health. "Our
collaboration with Prognos Health allows us to unlock the full
potential of genomics and a comprehensive RWD marketplace to bring
us closer to a future where personalized treatments are the
norm."
"We are thrilled to collaborate with BioReference Health, a
leader in genomic data and laboratory analytics," added
Sundeep Bhan, CEO of Prognos Health.
"Together, we intend to harness the power of actionable data to
accelerate drug discovery, help enable more effective diagnostics,
and enhance decision-making throughout the pharmaceutical and life
sciences domains and ultimately improve patient outcomes."
About BioReference Health,
LLC
BioReference® Health LLC, an OPKO Health,
Inc. Company (NASDAQ: OPK), empowers confident healthcare decisions
by prioritizing service, creating innovative solutions, and
offering scientific expertise in oncology, urology, and women's
health. Headquartered in Elmwood Park,
New Jersey, BioReference operates 10 laboratory facilities
around the country, is in-network with the largest health plans in
the United States and processes
more than 12 million tests annually. BioReference provides credible
and tailored solutions for a variety of customers and patients,
including medical practices small and large, hospitals and health
systems, correctional institutions, government agencies,
educational systems, and sport leagues. In addition to an extensive
test menu with 99 percent of tests performed in-house,
BioReference's differentiated offerings include large-scale health
screening programs, on-demand mobile phlebotomy, and transformative
business solutions that optimize laboratory management. For more
information visit https://www.bioreference.com/.
About Prognos Health
Prognos Health is a real-world
data (RWD) company that unlocks the power of data to improve
health. Prognos offers the leading managed RWD marketplace,
accelerating the development and delivery of innovative therapies
and improving health outcomes by offering fully integrated and
harmonized lab and health records on more than 325 million
de-identified patients. Prognos Health's platform provides a
comprehensive and integrated view of patient health, enabling
researchers, payers, and providers to make better decisions about
care. For more information, visit www.prognoshealth.com.
Media Contact:
Emily
Smith
media@bioreference.com
Ashley Triscuit
atriscuit@prognoshealth.com
View original
content:https://www.prnewswire.com/news-releases/bioreference-health-and-prognos-health-collaborate-to-advance-precision-medicine-and-testing-301998687.html
SOURCE BioReference Health, LLC